Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy

Inclusion Criteria: * History of seasonal allergic rhinitis from grass pollen * Normal electrocardiogram * Moderate to severe response to approx. 1500 grass pollen grains/m3 after 2 hrs of exposure in challenge chamber * Positive skin prick test for grass pollen at or within 12 months preceding screening visit * Positive RAST (class 2 or higher) for timothy grass pollen and to rPhl p 1 + rPhl p 5 at or within 12 months preceding screening visit Exclusion Criteria: * Pregnant or lactating females * Females with childbearing potential not using medically acceptable birth control * Structural nasal abnormalities, nasal polyposis, history of frequent nosebleeds, recent nasal surgery or ongoing upper respiratory tract infection * Any respiratory disease other than mild asthma controlled with occasional short acting beta agonists and normal lung function * Current or recent participation in another clinical trial * SIT for grass pollen allergy in the last two years prior to study * Past or present disease, which may affect outcome of the trial, judged by investigator * Autoimmune diseases, immune defects including immunosuppression, immune- complex immunopathies * Suspected hypersensitivity to any ingredients of study medication * Use of prohibited medication prior to screening and throughout study * depot corticosteroids (12 weeks) * oral corticosteroids (8 weeks) * inhaled corticosteroids (4 weeks) * Allergic symptoms at the time of screening